East China’s Jiangsu province has stepped up the construction of major investment projects and ensured their smooth progress through every possible effort so as to achieve the social and economic development targets set forth in this year’s government work report. JSBC has the story.
The Safes Antibody Drug Production Base was put into operation in Taizhou China Pharmaceutical High-tech Industrial Park last Saturday.
This high-tech innovative enterprise that has an internationally leading disposable biopharmaceutical production line and a matching filling line provides outsourcing services for antibody drug R&D and production.
The company's Ustekinumab Injection is the first monoclonal antibody to be launched in Phase III clinical trials before it is used for the treatment of psoriasis and inflammatory bowel disease.
Ustekinumab is a human monoclonal antibody directed against interleukin 12 and interleukin 23, naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders.
This product will break foreign monopolies, lower the price of similar medicines, and benefit the patients.
A freight train operated by China Railway Special Cargo Logistics Co.,Ltd. pulled into the port in Lianyungang city Sunday morning.
Port operators drove 309 Jianghuai vehicles off the special train. This batch of cars will be exported from Lianyungang Port to Mexico, which marks the opening of the sea-rail transport of vehicle between Hefei and Lianyungang and also the first of its kind in Anhui’s history.
The sea-rail transport has ensured that automakers in Anhui province will not be succumbed to the past transport mode integrating highway, inland river and railway containers, which has cut the cost and reduced the time spent on the transport.
